课题基金 / 基金详情

项目摘要

项目成果

Dai Fukumura的其他基金

相似基金

相关文献

中文摘要
翻译
我们实验室的一个标志是开发新颖和创新的体内肿瘤模型, 我们研究治疗药物输送的障碍。这是可能的,因为出色的外科手术 专业知识和独特的动物设施,在我们的实验室,这一核心作为其基础。这 核心将继续发挥两项功能:(i)手术支援,包括新的动物模型 发展;及(ii)饲养及饲养动物。两者都是成功完成所有 项目目标。因此,这一核心构成了我们PPG竞争性更新的基石。这一核心将 继续建立动物模型并提供给PPG的所有项目。透明窗口模型 - 乳房脂肪垫窗(所有三个项目)、颅骨窗(项目1、2)和背部皮肤 室(项目3)-能够在体内时间过程监测分子,细胞,解剖, 分别用于乳腺癌、脑癌和皮肤癌的原位器官环境中的功能参数。在 此外,自发性肿瘤使我们能够研究宿主微环境在肿瘤中的作用 发展和治疗。由这个核心维持的考克斯-7无菌动物群落使我们能够 在免疫缺陷小鼠中进行纵向生理学研究。这些研究极其困难 其他地方更贵。这个机构将继续为我们提供统一的实验动物 质量是免费的鼠病毒,致病菌和寄生虫。这使我们能够执行 不使用抗生素的外科手术。确定的植物群C3 H、FVB、C57 BL/6、裸菌、SCID、rag-T“ rag-T ′-,VTGFP-GFP/(FVB,C3 H,rag-Z ′-背景),Tie 2 p-GFP/(FVB,rag-T ′-背景),EF 1 cf- GFP/FVB和ACTbp-GFP/C57 VL/6小鼠目前可在考克斯-7设施中获得。额外 所有项目的转基因和基因敲除小鼠也将被工程化或再衍生、繁殖和维持 在设施内的所有项目。将对筛选出的且不含小鼠病原体的肿瘤进行系列研究。 体内传代并植入殖民地内的实验动物。体内肿瘤不会 传代超过第五代(F5),以避免肿瘤特征的变化。这保证了紧 控制动物和肿瘤的质量。核心C也将继续提供控释泵 植入、组织样本收集、血管线放置和术后护理。
英文摘要
A hallmark of our laboratory is the development of novel and innovative in vivo tumor models that allow us to study barriers to the delivery of therapeutic agents. This is possible due to the outstanding surgical expertise and unique animal facility available in our lab, for which this Core serves as its foundation. This Core will continue to serve two functions: (i) surgical support which includes novel animal model development, and (ii) breeding and maintenance of animals. Both are vital for successful completion of all project goals. Thus, this Core forms a cornerstone of the competing renewal of our PPG. This Core will continue to establish and provide animal models to all Projects of this PPG. Transparent window models - the mammary fat pad window (all three Projects), the cranial window (Projects 1, 2) and the dorsal skin chamber (Project 3)- enable in vivo time-course monitoring of molecular, cellular, anatomical, and functional parameters in orthotopic organ environments for breast, brain and skin cancers, respectively. In addition, spontaneous tumors allow us to study the role of the host microenvironment in tumor development and treatment. The Cox-7 gnotobiotic animal colony maintained by this Core allows us to carry out longitudinal physiological studies in immunodeficient mice. These studies are extremely difficult and more costly elsewhere. This facility will continue to provide us with experimental animals of uniform quality that are free of murine viruses, pathogenic bacteria, and parasites. This enables us to carry out surgical procedures without the use of antibiotics. Defined flora C3H, FVB,C57BL/6, Nude, SCID, rag-T'' rag-T'-, VTGFP-GFP/(FVB, C3H, rag-Z'' background), Tie2p-GFP/(FVB, rag-T'- background), EFlcf- GFP/FVB, and ACTbp-GFP/C57VL/6 mice are currently available in the Cox-7 facility. Additional transgenic and knock-out mice for all Projects will also be engineered or rederived, bred, and maintained for all Projects within the facility. Tumors that are screened and free of mouse pathogens will be serially passaged in vivo and implanted into experimental animals within the colony. In vivo tumors will not be passaged beyond the fifth generation (F5) to avoid changes in tumor characteristics. This assures tight control of the quality of animals and tumors. Core C will also continue to provide controlled-release pump implantation, tissue sample collection, vascular line placement, and post-surgical care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
  • 批准号:
    10582613
  • 项目类别:
  • 资助金额:
    $40.34万
  • 财政年份:
    2021
  • 负责人:
    Dai Fukumura
  • 依托单位:
Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2
  • 批准号:
    10394968
  • 项目类别:
  • 资助金额:
    $40.34万
  • 财政年份:
    2021
  • 负责人:
    Dai Fukumura
  • 依托单位:
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment
  • 批准号:
    9403496
  • 项目类别:
  • 资助金额:
    $49.51万
  • 财政年份:
    2017
  • 负责人:
    Dai Fukumura
  • 依托单位:
Overcoming Resistance to Anti-VEGF Treatment of Colorectal Cancers
  • 批准号:
    8463132
  • 项目类别:
  • 资助金额:
    $24.7万
  • 财政年份:
    2013
  • 负责人:
    Dai Fukumura
  • 依托单位:
海外基金